NEW YORK – Elevation Oncology on Wednesday announced that it had raised $65 million in a Series B financing round, led by new investors VenBio Partners and Cormorant Asset Management.
Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital, and existing investors also participated in the latest round, the funds from which Elevation will put toward completing enrollment in the Phase II CRESTONE trial and other corporate development activities.